Global private equity and venture capital news and research

Bridgepoint’s Diaverum exit hopes rise amid interest from trade giant Fresenius

26 Feb 2014

Thrasos Therapeutics kidney - AltAssets Private Equity NewsThe world’s biggest provider of dialysis treatment has admitted it could be interested in Bridgepoint-backed rival Diaverum as the buyout house looks for an exit.

Bridgepoint reportedly hired JP Morgan to review options for the business in January 2013, although firm spokesman James Murray denied it was attempting to sell the company at that point.

He added that it has since mandated JP Morgan, GE Capital, Commerzbank and Crédit Agricole to refinance the company’s senior debt with a new €708m senior facility.

Fresenius Medical Care CEO Rice Powell told Reuters his company would look at Diaverum if it was for sale.

Bridgepoint bought Diaverum in 2007 and has since expanded the group through more than 30 acquisitions.

The company operates about 270 clinics with more than 23,000 patients in 18 countries, up from 155 clinics at the time of Bridgepoint’s buyout.

Potential buyers could also include US companies such as Davita Healthcare Partners and Baxter, which JP Morgan helped acquire Sweden’s Gambro from EQT for $4bn in December.

Copyright © 2014 AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016